🇺🇸 FDA
Patent

US 7786290

Double-stranded ribonucleic acid with increased effectiveness in an organism

granted A61PA61P35/00A61P37/00

Quick answer

US patent 7786290 (Double-stranded ribonucleic acid with increased effectiveness in an organism) held by Alnylam Pharmaceuticals, Inc. expires Mon Aug 26 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Aug 31 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 26 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61P, A61P35/00, A61P37/00, A61P5/00, A61P7/00